Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.
To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Glucaric acid
Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Bhandari S et al. | A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients. | 2015 | Nephrol. Dial. Transplant. | pmid:25925701 |
Toblli JE et al. | Cardiovascular outcomes of intravenous iron in perspective of clinical trials and the use of different iron preparations. | 2015 | Int. J. Cardiol. | pmid:25838213 |
Dai P et al. | Triple Recycling Processes Impact Systemic and Local Bioavailability of Orally Administered Flavonoids. | 2015 | AAPS J | pmid:25762448 |
Toblli JE et al. | Changes in Echocardiographic Parameters in Iron Deficiency Patients with Heart Failure and Chronic Kidney Disease Treated with Intravenous Iron. | 2015 | Heart Lung Circ | pmid:25666998 |
Shiue E et al. | Improving product yields on D-glucose in Escherichia coli via knockout of pgi and zwf and feeding of supplemental carbon sources. | 2015 | Biotechnol. Bioeng. | pmid:25258165 |
Barot BS et al. | Physicochemical and structural characterization of iron-sucrose formulations: a comparative study. | 2014 | Pharm Dev Technol | pmid:23701359 |
Wang Y et al. | Hepatoprotective effects of kombucha tea: identification of functional strains and quantification of functional components. | 2014 | J. Sci. Food Agric. | pmid:23716136 |
Sasaki Y et al. | Hepcidin production in response to iron is controlled by monocyte-derived humoral factors. | 2014 | Int. J. Hematol. | pmid:24293278 |
Price E et al. | A prospective randomized wait list control trial of intravenous iron sucrose in older adults with unexplained anemia and serum ferritin 20-200 ng/mL. | 2014 | Blood Cells Mol. Dis. | pmid:25065855 |
Kuo KL et al. | Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. | 2014 | J. Am. Soc. Nephrol. | pmid:24722448 |
Macdougall IC et al. | A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. | 2014 | Clin J Am Soc Nephrol | pmid:24458078 |
Contreras C et al. | Comparative study of the oral absorption of microencapsulated ferric saccharate and ferrous sulfate in humans. | 2014 | Eur J Nutr | pmid:23892521 |
Corwin HL and Napolitano LM | Anemia in the critically ill: do we need to live with it?*. | 2014 | Crit. Care Med. | pmid:25126804 |
Pieracci FM et al. | A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical illness*. | 2014 | Crit. Care Med. | pmid:24797376 |
Hetzel D et al. | A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. | 2014 | Am. J. Hematol. | pmid:24639149 |
Perelló MF et al. | Intravenous ferrous sucrose versus placebo in addition to oral iron therapy for the treatment of severe postpartum anaemia: a randomised controlled trial. | 2014 | BJOG | pmid:24423186 |
Toyokuni S | Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis. | 2014 | Redox Rep. | pmid:24257681 |
Onken JE et al. | Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. | 2014 | Nephrol. Dial. Transplant. | pmid:23963731 |
Shah RB et al. | Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose. | 2014 | Int J Pharm | pmid:24440404 |
Tiwari P and Gupta KP | Modulation of miR-203 and its regulators as a function of time during the development of 7, 12 dimethylbenz [a] anthracene induced mouse skin tumors in presence or absence of the antitumor agents. | 2014 | Toxicol. Appl. Pharmacol. | pmid:24792773 |